Department of Defense gets $10 million raise to battle prostate cancer

The 2017 Defense Appropriations Bill greenlighted by the Senate last week includes a $10 billion increase, to $90 billion, for the Pentagon’s prostate cancer research program.

“The funding increase means many new prostate cancer research projects this year focused on new treatments and improving diagnosis methods,” says Jamie Bearse, CEO of the group ZERO: The End of Prostate Cancer, in a press release picked up by Prostate Cancer News Today.

The outlet notes that the Pentagon’s medical research programs have led to three new treatments for prostate cancer plus a genetic diagnosis profile.

Read the rest:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.